Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Department of Pathology, University of Chicago, Chicago, IL, USA.
Mod Pathol. 2019 Apr;32(4):490-498. doi: 10.1038/s41379-018-0165-9. Epub 2018 Nov 6.
The purpose of this study is to examine hematopoietic neoplasms with 9p24/JAK2 rearrangement including neoplasms associated with t(8;9)(p22;p24)/PCM1-JAK2 fusion neoplasm as well as cases with translocations involving 9p24/JAK2 and other partner genes. From seven large medical centers, we identified ten patients with t(8;9)(p22;p24) /PCM1-JAK2 and 3 with t(9p24;v)/JAK2 at diagnosis. Majority of the cases showed myeloproliferative neoplasm (MPN) associated features (n = 7) characterized by variable degrees of eosinophilia, myelofibrosis, frequent proliferations of early erythroblasts in bone marrow and extramedullary sites, and infrequent/absent somatic mutations. Other less common presentations included myelodysplastic syndromes (MDS) or MDS/MPN (one each). Four patients presented with B-lymphoblastic leukemia (B-ALL), and of them, two patients with t(8;9)(p22;p24.1) were proven to be B-lymphoblastic crisis of MPN; and the other two cases with t(9p24;v) both were de novo B-ALL, BCR-ABL1-like (Ph-like). We show that the hematopoietic neoplasms with 9p24/JAK2 rearrangement are extremely rare, and most of them are associated with t(8;9)(p22;p24)/PCM1-JAK2, a recent provisional World Health Organization entity under "myeloid/lymphoid neoplasm with a specific gene rearrangement". Cases of t(8;9)(p22;p24)/PCM1-JAK2, though heterogeneous, do exhibit some common clinicopathological characteristic features. Cases with t(9p24;v)/JAK2 are extremely rare; while such cases with a MPN presentation may resemble t(8;9)(p22;p24.1)/PCM1-JAK2, B-ALL cases presenting de novo B-ALL might belong to Ph-like B-ALL.
本研究旨在探讨 9p24/JAK2 重排的造血肿瘤,包括与 t(8;9)(p22;p24)/PCM1-JAK2 融合肿瘤相关的肿瘤以及涉及 9p24/JAK2 和其他伙伴基因的易位病例。我们从七个大型医疗中心中确定了 10 例 t(8;9)(p22;p24)/PCM1-JAK2 和 3 例 t(9p24;v)/JAK2 初诊病例。大多数病例表现出骨髓增殖性肿瘤(MPN)相关特征(n=7),特征为不同程度的嗜酸性粒细胞增多、骨髓纤维化、骨髓和骨髓外部位早期红细胞增殖频繁、体细胞突变罕见/缺失。其他不太常见的表现包括骨髓增生异常综合征(MDS)或 MDS/MPN(各 1 例)。4 例表现为 B 淋巴细胞白血病(B-ALL),其中 2 例 t(8;9)(p22;p24.1)患者被证实为 MPN 的 B 淋巴细胞白血病危象;另外 2 例 t(9p24;v)患者均为初发 B-ALL,BCR-ABL1 样(Ph 样)。我们表明,9p24/JAK2 重排的造血肿瘤极为罕见,大多数与 t(8;9)(p22;p24)/PCM1-JAK2 相关,后者是最近在“具有特定基因重排的髓系/淋巴系肿瘤”下提出的暂定的世界卫生组织实体。尽管 t(8;9)(p22;p24)/PCM1-JAK2 病例存在异质性,但确实表现出一些共同的临床病理特征。t(9p24;v)/JAK2 病例极为罕见;而具有 MPN 表现的病例可能与 t(8;9)(p22;p24.1)/PCM1-JAK2 相似,初发 B-ALL 病例可能属于 Ph 样 B-ALL。